FDA-cleared profile

Ceevra Reveal 3+

Ceevra, Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: CT and MR 3D segmentation, measurements and interactive models for adult preoperative and intraoperative surgical planning; not primary diagnosis.

Clinical role
Interactive 3D visualization and measurement aid for planning; it is not intended to replace clinical diagnosis or professional judgment.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Multi-region
Key limitation
Keep in mind: The FDA validation included 133 imaging studies with no more than one study per patient; model coverage and performance vary by structure and CT or MR input. The models are for planning and visualization, not primary diagnosis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: CT and MR 3D segmentation, measurements and interactive models for adult preoperative and intraoperative surgical planning; not primary diagnosis.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Multi-region Input: Adult CT or MR imaging studies processed by Ceevra models for supported anatomic structures.
  • Who uses it?Intended users: Healthcare professionals using 3D anatomical models for surgical planning and review.
  • What does the software produce?Output: Interactive 3D models with show, hide, rotate, zoom, pan and measurement controls for prostate, bladder, neurovascular bundles, kidneys, arteries, veins, pulmonary vessels, airways and bronchopulmonary segments as applicable to the model.
  • What is its most important limitation?Key limitation: The FDA validation included 133 imaging studies with no more than one study per patient; model coverage and performance vary by structure and CT or MR input. The models are for planning and visualization, not primary diagnosis.

Clinical takeaway. Clinical role: CT and MR 3D segmentation, measurements and interactive models for adult preoperative and intraoperative surgical planning; not primary diagnosis.

Evidence takeaway. Evidence from the reviewed source record: FDA validation covered 133 CT and MR imaging studies and reported structure-specific segmentation results, including prostate MR Dice similarity coefficient 0.90, kidney CT Dice similarity coefficient 0.92 and neurovascular-bundle MR 95th-percentile Hausdorff distance 6.6 mm.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
CT and MR 3D segmentation, measurements and interactive models for adult preoperative and intraoperative surgical planning; not primary diagnosis.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Interactive 3D visualization and measurement aid for planning; it is not intended to replace clinical diagnosis or professional judgment.
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Adult CT or MR imaging studies processed by Ceevra models for supported anatomic structures.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Interactive 3D models with show, hide, rotate, zoom, pan and measurement controls for prostate, bladder, neurovascular bundles, kidneys, arteries, veins, pulmonary vessels, airways and bronchopulmonary segments as applicable to the model.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Preoperative and intraoperative planning workflows using adult CT or MR studies.
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Healthcare professionals using 3D anatomical models for surgical planning and review.
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
The FDA validation included 133 imaging studies with no more than one study per patient; model coverage and performance vary by structure and CT or MR input. The models are for planning and visualization, not primary diagnosis.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
FDA validation covered 133 CT and MR imaging studies and reported structure-specific segmentation results, including prostate MR Dice similarity coefficient 0.90, kidney CT Dice similarity coefficient 0.92 and neurovascular-bundle MR 95th-percentile Hausdorff distance 6.6 mm.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA validation covered 133 CT and MR imaging studies and reported structure-specific segmentation results, including prostate MR Dice similarity coefficient 0.90, kidney CT Dice similarity coefficient 0.92 and neurovascular-bundle MR 95th-percentile Hausdorff distance 6.6 mm.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Prostate segmentation Dice similarity coefficient

0.9 Dice

  • EndpointSegmentation overlap
  • PopulationProstate MR studies in the exact 133-study validation set
  • Tested versionCeevra Reveal 3+ release reviewed in K243933

Kidney segmentation Dice similarity coefficient

0.92 Dice

  • EndpointSegmentation overlap
  • PopulationKidney CT studies in the exact 133-study validation set
  • Tested versionCeevra Reveal 3+ release reviewed in K243933

Neurovascular bundle 95th-percentile Hausdorff distance

6.6 mm

  • EndpointSegmentation boundary distance
  • PopulationNeurovascular-bundle MR studies in the exact 133-study validation set
  • Tested versionCeevra Reveal 3+ release reviewed in K243933

Ceevra Reveal 3+ multi-structure segmentation validation

  • DesignRetrospective multi-structure segmentation validation
  • PopulationAdult CT and MR imaging studies from the evaluated imaging systems and supported anatomy
  • Scopeexact submission
  • Tested versionCeevra Reveal 3+ release reviewed in K243933
  • Samplen=133
  • IndependenceSponsor or vendor study

K243933 FDA 510(k) summary

The FDA summary reports no more than one study per patient and structure-specific metrics across CT and MR models.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult CT or MR imaging studies processed by Ceevra models for supported anatomic structures.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Ceevra Reveal 3+, K243933

  2. Routing

    Source context, not route validation: Ceevra's current workflow page describes IT installation on end-user computers, PACS upload to a cloud workflow, and model viewing on computer, phone, tablet or a medical information system. These are family workflow claims, not an exact K243933 interface specification.

    Scope: Product family.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · Ceevra how it works and implementation overview

  3. AI processing

    Source context, not route validation: The FDA summary describes company-generated 3D models delivered to clinician viewers on desktop, mobile, external displays and virtual-reality viewers.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Ceevra Reveal 3+, K243933

  4. Returned objects

    Source context, not route validation: Interactive 3D models with show, hide, rotate, zoom, pan and measurement controls for prostate, bladder, neurovascular bundles, kidneys, arteries, veins, pulmonary vessels, airways and bronchopulmonary segments as applicable to the model.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Ceevra Reveal 3+, K243933

  5. Viewer/worklist/report

    Unresolved route: Interactive 3D models with show, hide, rotate, zoom, pan and measurement controls for prostate, bladder, neurovascular bundles, kidneys, arteries, veins, pulmonary vessels, airways and bronchopulmonary segments as applicable to the model.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Ceevra Reveal 3+, K243933

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA summary describes company-generated 3D models delivered to clinician viewers on desktop, mobile, external displays and virtual-reality viewers.
  • Exact FDA submission
  • Checked 2026-09-06
Integration
Ceevra's current workflow page describes IT installation on end-user computers, PACS upload to a cloud workflow, and model viewing on computer, phone, tablet or a medical information system. These are family workflow claims, not an exact K243933 interface specification.
  • Product family
  • Checked 2026-09-07

IT and PACS workflow

Ceevra's current family page describes IT installation on end-user computers and CT or MRI upload from PACS to a cloud workflow; exact K243933 interface details are not established.

product family · checked 2026-09-07

Multi-device model viewing

The family page describes viewing models on computer, phone, tablet and a medical information system, with structures tailored to the surgery and show/hide controls.

product family · checked 2026-09-07

Subscription purchasing

The family page describes annual volume-tiered subscriptions for multiple specialties or hospitals, with no one-time or variable fees; it gives no numeric amount or exact-release contract terms.

product family · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243933
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-03-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
22Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored candidate metadata contained empty PubMed and clinical-trial ID arrays; metadata was screened, not full-text or registry-reviewed. The stored recall candidate record was empty and no event was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor manual, peer reviewed publication, clinical trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    A family subscription structure is public, but no numeric price or exact K243933 contract amount was published.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Ceevra Reveal reimbursement CPT 3D"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-07 - Exact FDA submission

    The family page's HIPAA wording is not treated as a current exact-release security attestation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. K243933 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Ceevra Reveal 3+ model card (K243933)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) decision record and summary reviewed for Ceevra Reveal 3+, K243933

    U.S. Food and Drug Administration - Published 2025-03-04 - Accessed 2026-09-06

    Scope: identity, intended_use, performance, limitations, implementation

  8. Ceevra how it works and implementation overview

    Ceevra - Accessed 2026-09-07

    Scope: product_family, commercial_model, implementation, outputs

Research history

  1. K243933 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253270

Contour ProtégéAI+

Mim Software, Inc.

Authorized purpose: Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252539

Tempus Pixel

Arterys, Inc.

Authorized purpose: Multimodality DICOM image management, quantitative analysis, optional cardiovascular MR mapping and flow analysis, and therapy-response lesion tracking for trained clinicians.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2025-09-03
FDA-cleared K243647

Synapse PACS (7.5)

FUJIFILM Healthcare Americas Corporation

Authorized purpose: Synapse PACS version 7.5 provides primary processing and presentation of DICOM and supported non-DICOM images with measurement, segmentation, fusion, volume rendering, reporting, integrated 3D, two-point VOI, and AI-assisted bone removal.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2025-06-30
FDA-cleared K181892

Ziostation2

Ziosoft, Inc.

Authorized purpose: Ziostation2 is customer-hardware image-processing software for viewing, quantifying, manipulating, communicating, printing, and managing many radiological image types, with release-specific tools for lung and bronchoscopy planning, cardiac MR T1 mapping, and other advanced visualization.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2018-10-09

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history